2022 Visually Edited Data Items List

1) County of Residence at Diagnosis
2) Date of Diagnosis
3) Diagnostic Confirmation
4) Race Fields 1-5*
5) Site/Subsite*
6) Spanish/Hispanic Origin
7) Number of Regional Nodes Positive/Examined*
8) Laterality (Only paired sites listed in Volume I)
9) Histology – Type (for year of diagnosis)
10) Behavior
11) Grade Clinical
12) Grade Pathological
13) Grade Post therapy*
   a) Grade Post Therapy Clin (yc)
   b) Grade Post Therapy Path (yp)
14) EOD Mets
15) EOD Primary Tumor
16) EOD Regional Nodes
17) Tumor Size Clinical
18) Tumor Size Pathological
19) Tumor Size Summary
20) Surg Proc 1-3* fields a-f below
   a) RX Date Surgery
   b) RX Date Surgery Flag
   c) RX Date Surgical Procedure 1-3
   d) RX Date Surgery Procedure Flag 1-3
   e) RX Summ Surgical Margins
   f) Scope LN Proc 1-3
   g) Surg Other Proc 1-3
   h) Surg Prim 1-3
21) All Treatment data fields* (a-f below for Radiation, Chemo, Hormone, Immuno, Transplant/Endo, and Other)
   a) Radiation
      1. RX Date
      2. RX Date Flag
      3. Reason No Rad
      4. Rad Sequence
      5. Location of RX
      6. Phase I, II and III Radiation – each of the following:
         i. Radiation Treatment Modality
         ii. Radiation External Beam Planning Tech
   b) Chemotherapy
      1. RX Date
      2. RX Date Flag
3. Chemotherapy Sum
4. Chemotherapy at This Hosp
c) Hormone Therapy
   1. RX Date
   2. RX Date Flag
   3. Hormone Sum
   4. Hormone at This Hosp
d) Immunotherapy
   1. RX Date
   2. RX Date Flag
   3. Immunotherapy Sum
   4. Immunotherapy at This Hosp
e) Transplant/Endo Therapy
   1. RX Date
   2. RX Date Flag
   3. Transplant/Endo Sum
   4. Transplant/Endo at This Hosp
f) Other Therapy
   1. RX Date
   2. RX Date Flag
   3. Other Therapy Sum
   4. Other Therapy at This Hosp
g) Neoadjuvant
   1. Neoadjuvant Therapy
   2. Neoadjuvant Therapy – Clinical Response
   3. Neoadjuvant therapy – Treatment Effect

22) SEER SSF
23) Directly coded SEER Summary Stage 2018
24) Site Specific Data Items (SSDI)*

<table>
<thead>
<tr>
<th>SSDIs added in 2022</th>
<th>Excluded SSDIs in 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. LN Status: Pelvic</td>
<td>a. LN Status Femoral, Para-aortic and Pelvic</td>
</tr>
<tr>
<td>b. LN Status: Para-Aortic</td>
<td>b. Tumor Growth Pattern</td>
</tr>
<tr>
<td>c. LN Status: Femoral-Inguinal</td>
<td>c. Primary Sclerosing Cholangitis</td>
</tr>
<tr>
<td>d. p16</td>
<td></td>
</tr>
<tr>
<td>e. Macroscopic Evaluation of Mesorectum *</td>
<td></td>
</tr>
<tr>
<td>f. Lymphovascular Invasion **</td>
<td></td>
</tr>
</tbody>
</table>

**Although not officially an SSDI, the CCR will count this as an SSDI for VE purposes.

* Counted as a single discrepancy

**NOTE: Only CCR required Site Specific Data Items (SSDI) are to be visually edited**